NEKTAR THERAPEUTICS
7.30
USD
(+2.53%)
03/14/2025 - 16:30
Closed 15 min delayed data - NASDAQ Stocks
| Open: | 7.18 |
| Change: | +0.18 |
| Volume: | 5,145 |
| Low: | 7.10 |
| High: | 7.30 |
| High / Low range: | 0.20 |
| Type: | Stocks |
| Ticker: | NKTR |
| ISIN: |
NEKTAR THERAPEUTICS news, videos and press releases
For more news please use our advanced search feature.
NEKTAR THERAPEUTICS - More news...
NEKTAR THERAPEUTICS - More news...
- 03/12/2025 - 20:15 Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
- 03/05/2025 - 23:00 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
- 02/26/2025 - 12:00 Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
- 02/24/2025 - 12:00 Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
- 02/10/2025 - 12:00 Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
- 01/10/2025 - 12:00 Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
- 12/07/2024 - 17:00 Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
- 11/18/2024 - 20:30 Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
- 11/07/2024 - 21:15 Nektar Therapeutics Reports Third Quarter 2024 Financial Results
- 11/07/2024 - 15:15 Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting
- 11/06/2024 - 23:00 Nektar Therapeutics to Participate in Upcoming Investor Conferences
- 11/04/2024 - 13:30 Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama
- 10/31/2024 - 22:00 Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets
- 10/29/2024 - 13:00 Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
- 10/17/2024 - 16:07 Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
- 09/25/2024 - 07:30 Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
- 09/03/2024 - 13:00 Nektar Management to Present at Upcoming Investor Conferences
- 08/08/2024 - 20:15 Nektar Therapeutics Reports Second Quarter 2024 Financial Results
- 08/01/2024 - 22:00 Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets
- 06/12/2024 - 13:30 Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
- 05/30/2024 - 22:00 Nektar Management to Present at Upcoming Investor Conferences
- 05/09/2024 - 20:15 Nektar Therapeutics Reports First Quarter 2024 Financial Results
- 05/02/2024 - 22:00 Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
- 03/22/2024 - 18:00 Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
- 03/05/2024 - 14:00 Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
- 03/04/2024 - 21:15 Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
- 03/04/2024 - 13:30 Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
- 02/27/2024 - 23:00 Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
- 02/26/2024 - 23:00 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
- 01/03/2024 - 23:00 Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
